Indian Pharma Stocks Drop Amid U.S. Generics Concerns

  Published 9 months ago

Indian pharma stocks fall as Macquarie warns of U.S. generics price erosion and downgrades key firms.

  • NIPHARM drops 1.5% as 17/20 Nifty 50 pharma stocks decline amid rising competition.
  • Macquarie cites easing U.S. drug shortages and increased competition accelerating price erosion.
  • Aurobindo, Cipla, Dr. Reddy's, Lupin downgraded; Q1 results at risk from gRevlimid competition.

You might like these

RBI Cuts Rates 50 Bps, Shifts to Neutral Stance

India's Offshore Shipbuilding Boost

RoDTEP Benefits Restored: ASSOCHAM Praises Move

Gangwal Cuts IndiGo Stake to 4.71%

Eris Lifesciences: Rating Boost Despite Missed Estimates

Thyrocare Q1 Profit Soars 50%

Jio BlackRock Launches Low-Cost Funds in India

News that matters the most ⚡